Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Typ-2-Diabetes und Adipositas Klimawandel und Gesundheit Neues aus dem Markt COVID-19 Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Häufige urologisch-sexualmedizinische Themen in der Praxis sind das Thema des MMW-Webinars am 5. Juni von 17.30 bis 19 Uhr. Konkret geht es um die Frage, wann bei Harnwegsinfektionen auf Antibiotika verzichtet werden kann, und um ein Update zur Therapie von Libido- und Potenzstörungen des Mannes. Der dritte Vortrag behandelt sexuell übertragbare Krankheiten. Stellen Sie Ihre Fragen an die Experten und sammeln Sie 2 CME-Punkte. Jetzt gleich anmelden!
Erweiterte Suche
Anmelden
nach oben
Clinical Reviews in Allergy & Immunology
Erschienen in: Clinical Reviews in Allergy & Immunology 2-3/2010

01.04.2010

Contemporary Challenges in Mastocytosis

verfasst von: H. David Pettigrew, Suzanne S. Teuber, James S. Kong, M. Eric Gershwin

Erschienen in: Clinical Reviews in Allergy & Immunology | Ausgabe 2-3/2010

Einloggen, um Zugang zu erhalten

Abstract

Mastocytosis denotes a wide range of disorders characterized by having abnormal growth and accumulation of mast cells. Mast cells contain histamine and other inflammatory mediators, which have diverse actions within the body, and play crucial roles in acquired and innate immunity. The diverse actions of these inflammatory mediators can lead to puzzling symptoms in individuals with mastocytosis. These symptoms can include flushing, pruritis, nausea, vomiting, abdominal pain, diarrhea, vascular instability, and headache. These clinical features generally divide into cutaneous and systemic manifestations, giving rise to the two divisions of mastocytosis: cutaneous mastocytosis (CM) and systemic mastocytosis. CM has a highly favorable clinical prognosis. Systemic mastocytosis has a range of severity, with the milder forms often remaining chronic conditions, while the severe forms have rapid complex courses with poor prognoses. Generally, treatment is aimed at avoiding mast cell degranulation, inhibiting the actions of the constitutive mediators released by mast cells and, in severe cases, cytoreductive and polychemotherapeutic agents. Behavioral intervention includes avoidance of triggers, such as heat, cold, pressure, exercise, sunlight, and strong emotions. Treatment for released histamine and other inflammatory mediators includes H1 antihistamines, H2 antihistamines, proton pump inhibitors, anti-leukotriene agents, and injectible epinephrine (for possible anaphylaxis). For severe cases, treatment includes cytoreductive agents (interferon alpha, glucocorticoids, and cladribine) and polychemotherapeutic agents (daunomycin, etoposide, and 6-mercaptopurine). For very specific and severe cases, tyrosine kinase inhibitors, imatinib and midostaurine, have shown promise.
Literatur
1.
Nettleship E, Tay W (1869) Rare forms of urticaria. Br Med J 2:323–330CrossRef
2.
Unna PG (1894) Die spezifische farbung der mastzellenkornung. Monatsh Prakt Dermatol 19:367–368
3.
Ellis JM (1949) Urticaria pigmentosa: a report of a case with autopsy. AMA Arch Pathol 48:426–435
4.
5.
Jorpes J (1939) The site of formation of heparin. In: Jorpes JE (ed) Heparin: its chemistry, physiology, and application in medicine. Oxford University Press, Oxford, pp 30–39
6.
7.
Valent P, Sillaber C, Bettelheim P (1991) The growth and differentiation of mast cells. Prog Growth Factor Res 3(1):27–41CrossRefPubMed
8.
Kirshenbaum AS et al (1999) Demonstration that human mast cells arise from a progenitor cell population that is CD34(+), c-kit(+), and expresses aminopeptidase N (CD13). Blood 94(7):2333–2342PubMed
9.
Kirshenbaum AS et al (1991) Demonstration of the origin of human mast cells from CD34+ bone marrow progenitor cells. J Immunol 146(5):1410–1415PubMed
10.
Saavedra-Delgado AM, Turpin S, Metcalfe DD (1984) Typical and atypical mast cells of the rat gastrointestinal system: distribution and correlation with tissue histamine. Agents Actions 14(1):1–7CrossRefPubMed
11.
Metcalfe DD, Baram D, Mekori YA (1997) Mast cells. Physiol Rev 77(4):1033–1079PubMed
12.
Kirshenbaum AS et al (1992) Effect of IL-3 and stem cell factor on the appearance of human basophils and mast cells from CD34+ pluripotent progenitor cells. J Immunol 148(3):772–777PubMed
13.
Valent P et al (1992) Induction of differentiation of human mast cells from bone marrow and peripheral blood mononuclear cells by recombinant human stem cell factor/kit-ligand in long-term culture. Blood 80(9):2237–2245PubMed
14.
Sperr WR et al (2001) Morphologic properties of neoplastic mast cells: delineation of stages of maturation and implication for cytological grading of mastocytosis. Leuk Res 25(7):529–536CrossRefPubMed
15.
Furitsu T et al (1993) Identification of mutations in the coding sequence of the proto-oncogene c-kit in a human mast cell leukemia cell line causing ligand-independent activation of c-kit product. J Clin Invest 92(4):1736–1744CrossRefPubMed
16.
Longley BJ et al (1996) Somatic c-KIT activating mutation in urticaria pigmentosa and aggressive mastocytosis: establishment of clonality in a human mast cell neoplasm. Nat Genet 12(3):312–314CrossRefPubMed
17.
Nagata H et al (1995) Identification of a point mutation in the catalytic domain of the protooncogene c-kit in peripheral blood mononuclear cells of patients who have mastocytosis with an associated hematologic disorder. Proc Natl Acad Sci U S A 92(23):10560–10564CrossRefPubMed
18.
Echtenacher B, Mannel DN, Hultner L (1996) Critical protective role of mast cells in a model of acute septic peritonitis. Nature 381(6577):75–77CrossRefPubMed
19.
Varadaradjalou S et al (2003) Toll-like receptor 2 (TLR2) and TLR4 differentially activate human mast cells. Eur J Immunol 33(4):899–906CrossRefPubMed
20.
Kulka M et al (2004) Activation of mast cells by double-stranded RNA: evidence for activation through Toll-like receptor 3. J Allergy Clin Immunol 114(1):174–182CrossRefPubMed
21.
Metcalfe DD (1991) Classification and diagnosis of mastocytosis: current status. J Invest Dermatol 96(3):2S–4SCrossRef
22.
Valent P et al (2001) Diagnostic criteria and classification of mastocytosis: a consensus proposal. Leuk Res 25(7):603–625CrossRefPubMed
23.
Kong JS et al (2006) Mastocytosis: the great masquerader. Clin Rev Allergy Immunol 30(1):53–60CrossRefPubMed
24.
Horny HP, Sotlar K, Valent P (2007) Mastocytosis: state of the art. Pathobiology 74(2):121–132CrossRefPubMed
25.
Hartmann K, Metcalfe DD (2000) Pediatric mastocytosis. Hematol Oncol Clin North Am 14(3):625–640CrossRefPubMed
26.
Wolff K, Komar M, Petzelbauer P (2001) Clinical and histopathological aspects of cutaneous mastocytosis. Leuk Res 25(7):519–528CrossRefPubMed
27.
Hartmann K, Henz BM (2002) Cutaneous mastocytosis—clinical heterogeneity. Int Arch Allergy Immunol 127(2):143–146CrossRefPubMed
28.
Roupe G, Granerus G, Olafson JH (1983) Urticaria pigmentosa or systemic mastocytosis? J Am Acad Dermatol 8(1):137CrossRefPubMed
29.
30.
Topar G et al (1998) Urticaria pigmentosa: a clinical, hematopathologic, and serologic study of 30 adults. Am J Clin Pathol 109(3):279–285PubMed
31.
Findlay GH, Schulz EJ, Pepler WJ (1960) Diffuse cutaneous mastocytosis. S Afr Med J 34:353–356PubMed
32.
Waxtein LM et al (2000) Diffuse cutaneous mastocytosis with bone marrow infiltration in a child: a case report. Pediatr Dermatol 17(3):198–201CrossRefPubMed
33.
Willemze R et al (1980) Diffuse cutaneous mastocytosis with multiple cutaneous mastocytomas. Report of a case with clinical, histopathological and ultrastructural aspects. Br J Dermatol 102(5):601–607CrossRefPubMed
34.
Scheck O et al (1987) Solitary mastocytoma of the eyelid. A case report with special reference to the immunocytology of human tissue mast cells, and a review of the literature. Virchows Arch A Pathol Anat Histopathol 412(1):31–36CrossRefPubMed
35.
Sperr WR et al (2002) Serum tryptase levels in patients with mastocytosis: correlation with mast cell burden and implication for defining the category of disease. Int Arch Allergy Immunol 128(2):136–141CrossRefPubMed
36.
Schwartz LB (2006) Diagnostic value of tryptase in anaphylaxis and mastocytosis. Immunol Allergy Clin North Am 26(3):451–463CrossRefPubMed
37.
Schwartz LB et al (1995) The alpha form of human tryptase is the predominant type present in blood at baseline in normal subjects and is elevated in those with systemic mastocytosis. J Clin Invest 96(6):2702–2710CrossRefPubMed
38.
Schwartz LB et al (1987) Tryptase levels as an indicator of mast-cell activation in systemic anaphylaxis and mastocytosis. N Engl J Med 316(26):1622–1626PubMed
39.
Schwartz LB (1994) Tryptase: a clinical indicator of mast cell-dependent events. Allergy Proc 15(3):119–123CrossRefPubMed
40.
41.
Stevens EC, Rosenthal NS (2001) Bone marrow mast cell morphologic features and hematopoietic dyspoiesis in systemic mast cell disease. Am J Clin Pathol 116(2):177–182CrossRefPubMed
42.
Pardanani A et al (2003) Differential expression of CD2 on neoplastic mast cells in patients with systemic mast cell disease with and without an associated clonal haematological disorder. Br J Haematol 120(4):691–694CrossRefPubMed
43.
Jordan JH et al (2001) Immunohistochemical properties of bone marrow mast cells in systemic mastocytosis: evidence for expression of CD2, CD117/Kit, and bcl-x(L). Hum Pathol 32(5):545–552CrossRefPubMed
44.
Longley BJ Jr et al (1999) Activating and dominant inactivating c-KIT catalytic domain mutations in distinct clinical forms of human mastocytosis. Proc Natl Acad Sci U S A 96(4):1609–1614CrossRefPubMed
45.
Akin C et al (2000) Analysis of the surface expression of c-kit and occurrence of the c-kit Asp816Val activating mutation in T cells, B cells, and myelomonocytic cells in patients with mastocytosis. Exp Hematol 28(2):140–147CrossRefPubMed
46.
Feger F et al (2002) Kit and c-kit mutations in mastocytosis: a short overview with special reference to novel molecular and diagnostic concepts. Int Arch Allergy Immunol 127(2):110–114CrossRefPubMed
47.
Kemmer K et al (2004) KIT mutations are common in testicular seminomas. Am J Pathol 164(1):305–313PubMed
48.
Horny HP et al (2003) Increase of bone marrow lymphocytes in systemic mastocytosis: reactive lymphocytosis or malignant lymphoma? Immunohistochemical and molecular findings on routinely processed bone marrow biopsy specimens. J Clin Pathol 56(8):575–578CrossRefPubMed
49.
Sagher F, Cohen C, Schorr S (1952) Concomitant bone changes in urticaria pigmentosa. J Invest Dermatol 18(6):425–432PubMed
50.
Escribano L et al (1998) Indolent systemic mast cell disease in adults: immunophenotypic characterization of bone marrow mast cells and its diagnostic implications. Blood 91(8):2731–2736PubMed
51.
Horny HP et al (2004) Systemic mastocytosis with associated clonal haematological non-mast cell lineage diseases: a histopathological challenge. J Clin Pathol 57(6):604–608CrossRefPubMed
52.
Horny HP et al (1990) Blood findings in generalized mastocytosis: evidence of frequent simultaneous occurrence of myeloproliferative disorders. Br J Haematol 76(2):186–193CrossRefPubMed
53.
Sperr WR et al (2000) Clinical and biologic diversity of leukemias occurring in patients with mastocytosis. Leuk Lymphoma 37(5–6):473–486PubMed
54.
Travis WD et al (1986) Mast cell leukemia: report of a case and review of the literature. Mayo Clin Proc 61(12):957–966PubMed
55.
Worobec AS (2000) Treatment of systemic mast cell disorders. Hematol Oncol Clin North Am 14(3):659–687 viiCrossRefPubMed
56.
Guenther PP et al (2001) Temporary response of localized intracranial mast cell sarcoma to combination chemotherapy. J Pediatr Hematol Oncol 23(2):134–138CrossRefPubMed
57.
58.
Kojima M et al (1999) Mast cell sarcoma with tissue eosinophilia arising in the ascending colon. Mod Pathol 12(7):739–743PubMed
59.
Wolff K (2002) Treatment of cutaneous mastocytosis. Int Arch Allergy Immunol 127(2):156–159CrossRefPubMed
60.
Castells M, Akin C (2008) Treatment and prognosis of mastocytosis (cutaneous and systemic). Up to Date; www.​utdol.​com, accessed 9 Apr 2009
61.
Valent P et al (2007) Standards and standardization in mastocytosis: consensus statements on diagnostics, treatment recommendations and response criteria. Eur J Clin Invest 37(6):435–453CrossRefPubMed
62.
Wilson TM, Metcalfe DD, Robyn J (2006) Treament of systemic mastocytosis. Immunol Allergy Clin Nort Am 26(3):549-573CrossRef
63.
Pardanani A, Akin C, Valent P (2006) Pathogenesis, clinical features, and treatment advances in mastocytosis. Best Pract Res Clin Haematol 19(3):595-615CrossRefPubMed
64.
Gonzalez de Olano D et al (2008) Safety and effectiveness of immunotherapy in patients with indolent systemic mastocytois presenting with Hymenoptera venom anaphylaxis. J Allergy Clin Immunol 121(2):519-526CrossRefPubMed
65.
Kluin-Nelemans HC et al (1992) Response to interferon alfa-2b in a patient with systemic mastocytosis. N Engl J Med 326(9):619–623PubMedCrossRef
66.
Tefferi A et al (2001) Treatment of systemic mast-cell disease with cladribine. N Engl J Med 344(4):307–309CrossRefPubMed
67.
Kluin-Nelemans HC et al (2003) Cladribine therapy for systemic mastocytosis. Blood 102(13):4270–4276CrossRefPubMed
68.
Valent P et al (2003) Diagnosis and treatment of systemic mastocytosis: state of the art. Br J Haematol 122(5):695–717CrossRefPubMed
69.
70.
Akin C et al (2004) A novel form of mastocytosis associated with a transmembrane c-kit mutation and response to imatinib. Blood 103(8):3222–3225CrossRefPubMed
71.
Ma Y et al (2002) The c-KIT mutation causing human mastocytosis is resistant to STI571 and other KIT kinase inhibitors; kinases with enzymatic site mutations show different inhibitor sensitivity profiles than wild-type kinases and those with regulatory-type mutations. Blood 99(5):1741–1744CrossRefPubMed
72.
Akin C et al (2003) Effects of tyrosine kinase inhibitor STI571 on human mast cells bearing wild-type or mutated c-kit. Exp Hematol 31(8):686–692CrossRefPubMed
73.
Musto P et al (2004) Inefficacy of imatinib-mesylate in sporadic, aggressive systemic mastocytosis. Leuk Res 28(4):421–422CrossRefPubMed
74.
Gotlib J et al (2005) Activity of the tyrosine kinase inhibitor PKC412 in a patient with mast cell leukemia with the D816V KIT mutation. Blood 106(8):2865–2870CrossRefPubMed
Metadaten
Titel
Contemporary Challenges in Mastocytosis
verfasst von
H. David Pettigrew
Suzanne S. Teuber
James S. Kong
M. Eric Gershwin
Publikationsdatum
01.04.2010
Verlag
Humana Press Inc
Erschienen in
Clinical Reviews in Allergy & Immunology / Ausgabe 2-3/2010
Print ISSN: 1080-0549
Elektronische ISSN: 1559-0267
DOI
https://doi.org/10.1007/s12016-009-8164-8

Weitere Artikel der Ausgabe 2-3/2010

Clinical Reviews in Allergy & Immunology 2-3/2010 Zur Ausgabe

OriginalPaper

Predictors of Pregnancy Outcome in Antiphospholipid Syndrome: A Review

OriginalPaper

The Pathogenesis of Neural Injury in Animal Models of the Antiphospholipid Syndrome

EditorialNotes

Challenges for the Autoimmunologist

OriginalPaper

Can Lupus Flares be Associated with Tuberculosis Infection?

OriginalPaper

Efficacy and Safety of Anti-Tumour Necrosis Factor in Elderly Patients with Rheumatoid Arthritis: An Observational Study

OriginalPaper

Mycobacterium Tuberculosis, Autoimmunity, and Vitamin D

Neu im Fachgebiet HNO

Erhebliches Risiko für Kehlkopfkrebs bei mäßiger Dysplasie

29.05.2024 Larynxkarzinom Nachrichten

Fast ein Viertel der Personen mit mäßig dysplastischen Stimmlippenläsionen entwickelt einen Kehlkopftumor. Solche Personen benötigen daher eine besonders enge ärztliche Überwachung.

Hörschwäche erhöht Demenzrisiko unabhängig von Beta-Amyloid

29.05.2024 Hörstörungen Nachrichten

Hört jemand im Alter schlecht, nimmt das Hirn- und Hippocampusvolumen besonders schnell ab, was auch mit einem beschleunigten kognitiven Abbau einhergeht. Und diese Prozesse scheinen sich unabhängig von der Amyloidablagerung zu ereignen.

„Übersichtlicher Wegweiser“: Lauterbachs umstrittener Klinik-Atlas ist online

17.05.2024 Klinik aktuell Nachrichten

Sie sei „ethisch geboten“, meint Gesundheitsminister Karl Lauterbach: mehr Transparenz über die Qualität von Klinikbehandlungen. Um sie abzubilden, lässt er gegen den Widerstand vieler Länder einen virtuellen Klinik-Atlas freischalten.

Betalaktam-Allergie: praxisnahes Vorgehen beim Delabeling

16.05.2024 Pädiatrische Allergologie Nachrichten

Die große Mehrheit der vermeintlichen Penicillinallergien sind keine. Da das „Etikett“ Betalaktam-Allergie oft schon in der Kindheit erworben wird, kann ein frühzeitiges Delabeling lebenslange Vorteile bringen. Ein Team von Pädiaterinnen und Pädiatern aus Kanada stellt vor, wie sie dabei vorgehen.

Update HNO

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert – ganz bequem per eMail.

Newsletter bestellen
Bildnachweise